Skip to Content
 
 
 
 

Published on March 30, 2022

Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care

Theralink’s RPPA (Reverse Phase Protein Array) Technology to be deployed to support and enhance Genomic insights and may ultimately help improve patient care.

Avera Health and Theralink Technologies, a precision medicine company with a novel phosphoprotein-based assay for breast cancer, announced a strategic collaboration to advance comprehensive molecular profiling, enabling Avera Health’s providers and patients to benefit from data-driven insights that inform targeted cancer treatments.

Avera has a long-standing history of leading the way in precision oncology with patients’ tumors being genetically sequenced to guide individualized cancer care. Theralink, with its patented protein and phosphoprotein biomarker platform and lab developed test, is the only commercially available assay for clinical use that measures the tumor cell levels of activated proteins, which are the primary targets of most FDA-approved therapies and biopharmaceutical investigational drugs.

Theralink will provide key patient-specific information about which drug targets are activated and “in use” in each patient tumor sample. This information, coupled with the genomics findings, will provide a comprehensive molecular profile for all Avera oncology patients by way of a multiomic report used for physician treatment decisions.

”Avera has been a cancer care leader in our region for many years. Avera Cancer Institute is focused on actionable insights for our physicians and patients to make treatment decisions that are personalized,” said Casey Williams, Chief Scientific Officer and Executive Director of Cancer Research. “We understand the role this innovative approach plays in generating better health outcomes for our patients, and Theralink will play a key role in that process.”

“We believe that the Theralink protein/phosphoprotein data, combined with the next generation sequencing data, may give Avera Cancer Institute the most cutting edge and best precision oncology data in the world, potentially creating a step change in cancer care,” said Mick Ruxin, M.D., President & CEO of Theralink. He went on to say, “It is gratifying to know that a large, prestigious, midwest cancer program, Avera Health, has realized the significant potential value of our Theralink assay for their cancer patients.” Dr. Ruxin continued, “We expect great results from working with Avera and their patients in our goal to decrease the morbidity and mortality of cancer patients.”

As part of this collaboration, Avera will assist Theralink Technologies in validating new clinical assays for additional tumors (such as GYN, Head and Neck, GI, Lung, Kidney, Liver and Prostate) through retrospective case analysis and population-based data. This may bring new capability and insights to precision oncology care and allow for the Theralink assay to become a pan-tumor assay.

Stay up to date!

Visit News & Media to get the latest from Avera Health.

Media Contact

For media inquiries, please contact:

Avera Media Team
Phone: 605-322-7790
Email: Media@Avera.org

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.